New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
chemotherapy
cholaniocarcinoma
immunotherapy
molecular landscape
targeted-therapy
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
11 03 2020
11 03 2020
Historique:
received:
01
02
2020
revised:
28
02
2020
accepted:
28
02
2020
entrez:
15
3
2020
pubmed:
15
3
2020
medline:
17
3
2021
Statut:
epublish
Résumé
Cholangiocarcinoma (CCA) represents a disease entity that comprises a heterogeneous group of biliary malignant neoplasms, with variable clinical presentation and severity. It may be classified according to its anatomical location and distinguished in intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA), each subtype implying distinct epidemiology, biology, prognosis, and strategy for clinical management. Its incidence has increased globally over the past few decades, and its mortality rate remains high due to both its biological aggressiveness and resistance to medical therapy. Surgery is the only potentially curative treatment and is the standard approach for resectable CCA; however, more than half of the patients have locally advanced or metastatic disease at presentation. For patients with unresectable CCA, the available systemic therapies are of limited effectiveness. However, the advances of the comprehension of the complex molecular landscape of CCA and its tumor microenvironment could provide new keys to better understand the pathogenesis, the mechanisms of resistance and ultimately to identify promising new therapeutic targets. Recently, clinical trials targeting isocitrate dehydrogenase (IDH)-1 mutations and fibroblast growth factor receptor (FGFR)-2 fusions, as well as immunotherapy showed promising results. All these new and emerging therapeutic options are herein discussed.
Identifiants
pubmed: 32168869
pii: cells9030688
doi: 10.3390/cells9030688
pmc: PMC7140695
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Oncotarget. 2017 Jan 31;8(5):7710-7721
pubmed: 28032598
Liver Int. 2019 May;39 Suppl 1:43-62
pubmed: 30903728
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
Oncologist. 2012;17(1):72-9
pubmed: 22180306
PLoS One. 2013;8(1):e54499
pubmed: 23349909
Invest New Drugs. 2018 Jun;36(3):424-434
pubmed: 28965185
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19513-8
pubmed: 24154728
Br J Surg. 2018 Feb;105(3):192-202
pubmed: 29405274
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
J Hepatol. 2014 Jun;60(6):1268-89
pubmed: 24681130
Liver Int. 2019 May;39(5):914-923
pubmed: 30716200
Mod Pathol. 2014 Jul;27(7):1028-34
pubmed: 24309328
Ann Hepatobiliary Pancreat Surg. 2019 Nov;23(4):403-407
pubmed: 31825009
Am J Pathol. 2019 Oct;189(10):2090-2101
pubmed: 31351075
Visc Med. 2019 Mar;35(1):28-37
pubmed: 31312647
J Clin Oncol. 2018 Jan 20;36(3):276-282
pubmed: 29182496
Cancer Chemother Pharmacol. 2010 May;65(6):1101-7
pubmed: 19707761
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Ann Surg. 2007 May;245(5):755-62
pubmed: 17457168
JAMA Oncol. 2019 Jun 1;5(6):824-830
pubmed: 30998813
Cancers (Basel). 2019 Feb 22;11(2):
pubmed: 30813354
J Hepatol. 2012 Jul;57(1):69-76
pubmed: 22420979
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
J Int Med Res. 2019 Jun;47(6):2768-2777
pubmed: 31106632
Am J Surg. 2004 Apr;187(4):538-42
pubmed: 15041507
J Clin Oncol. 2011 Jun 10;29(17):2357-63
pubmed: 21519026
Cancer Chemother Pharmacol. 2009 Sep;64(4):777-83
pubmed: 19169683
Development. 2009 May;136(10):1727-39
pubmed: 19369401
Annu Rev Immunol. 2012;30:677-706
pubmed: 22224761
Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Oncologist. 2017 Jul;22(7):804-810
pubmed: 28487467
Ann Oncol. 2016 Sep;27(suppl 5):v28-v37
pubmed: 27664259
Chemotherapy. 2014;60(1):13-23
pubmed: 25341559
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Ann Oncol. 2014 Jul;25(7):1416-21
pubmed: 24737778
Eur J Surg Oncol. 2007 Oct;33(8):1025-9
pubmed: 17400419
Lancet Oncol. 2015 Aug;16(8):967-78
pubmed: 26179201
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1454-1460
pubmed: 28844952
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111
pubmed: 28994423
PLoS One. 2011 Jan 06;6(1):e15640
pubmed: 21253578
Chin Clin Oncol. 2016 Oct;5(5):62
pubmed: 27829276
Oncology. 2012;82(3):175-9
pubmed: 22433475
Surg Today. 2012 Aug;42(8):770-5
pubmed: 22407314
Oncotarget. 2015 Dec 8;6(39):42276-89
pubmed: 26474277
J Hepatol. 2017 Sep;67(3):632-644
pubmed: 28389139
Cancer Metastasis Rev. 2017 Mar;36(1):141-157
pubmed: 27981460
Cancer Discov. 2017 Sep;7(9):943-962
pubmed: 28818953
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Anticancer Res. 2017 Sep;37(9):5193-5197
pubmed: 28870954
Br J Cancer. 2010 Aug 10;103(4):469-74
pubmed: 20628385
Ann Surg. 2008 Jul;248(1):84-96
pubmed: 18580211
Oncologist. 2014 Mar;19(3):235-42
pubmed: 24563076
J Hepatol. 2020 Feb;72(2):353-363
pubmed: 31954497
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
J Hepatobiliary Pancreat Sci. 2014 Oct;21(10):767-76
pubmed: 25044480
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Cancer Control. 2017 Jul-Sep;24(3):1073274817729245
pubmed: 28975830
Z Gastroenterol. 2016 May;54(5):426-30
pubmed: 27171333
Hepatology. 2016 Nov;64(5):1785-1791
pubmed: 27177447
Anticancer Res. 1999 May-Jun;19(3B):2257-60
pubmed: 10472340
Ann Oncol. 2014 Feb;25(2):391-8
pubmed: 24351397
Ann Surg Oncol. 2016 Aug;23(8):2610-7
pubmed: 27012989
Lancet Oncol. 2014 Jul;15(8):819-28
pubmed: 24852116
JAMA Oncol. 2017 Jan 1;3(1):106-112
pubmed: 27812682
J Gastrointest Oncol. 2016 Dec;7(6):E98-E102
pubmed: 28078132
J Clin Oncol. 2015 Oct 20;33(30):3401-8
pubmed: 26324363
Cancer Discov. 2013 Jun;3(6):636-47
pubmed: 23558953
Cancer Res. 2003 Mar 1;63(5):1083-92
pubmed: 12615726
Cancer Discov. 2017 May;7(5):459-461
pubmed: 28461409
PLoS One. 2017 Oct 19;12(10):e0186643
pubmed: 29049401
Lancet Oncol. 2012 Feb;13(2):181-8
pubmed: 22192731
Br J Cancer. 2011 Jun 28;105(1):131-8
pubmed: 21673683
J Clin Oncol. 2019 Mar 10;37(8):658-667
pubmed: 30707660
Medicina (Kaunas). 2019 Feb 08;55(2):
pubmed: 30743998
J Hematol Oncol. 2015 May 29;8:58
pubmed: 26022204
Br J Cancer. 2019 Jan;120(2):165-171
pubmed: 30420614
Br J Cancer. 2018 Oct;119(7):815-822
pubmed: 30206366
JAMA. 2012 Jul 11;308(2):147-56
pubmed: 22782416
Ann Oncol. 2016 Jan;27(1):134-40
pubmed: 26483051
Int J Mol Med. 2016 Jul;38(1):3-15
pubmed: 27245147
Cancer. 2002 Oct 15;95(8):1685-95
pubmed: 12365016
Oncotarget. 2017 Apr 11;8(15):24644-24651
pubmed: 28445951
HPB (Oxford). 2017 Sep;19(9):741-748
pubmed: 28684194
J Clin Oncol. 2012 Jun 1;30(16):1934-40
pubmed: 22529261
Ann Oncol. 2014 Dec;25(12):2328-38
pubmed: 24769639
Sci Rep. 2019 May 21;9(1):7643
pubmed: 31113993
BMC Cancer. 2015 Jul 31;15:564
pubmed: 26228433
Cancer. 2019 Mar 15;125(6):902-909
pubmed: 30561756
Clin Cancer Res. 2016 Jan 1;22(1):16-9
pubmed: 26553750
Lancet Oncol. 2010 Jan;11(1):48-54
pubmed: 19932054
Cancer Manag Res. 2013 Dec 11;9:1-3
pubmed: 24376362
J Clin Invest. 2015 Sep;125(9):3335-7
pubmed: 26325031
Curr Opin Gastroenterol. 2014 May;30(3):295-302
pubmed: 24569570
PLoS One. 2014 Dec 23;9(12):e115383
pubmed: 25536104
Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4869-77
pubmed: 25349422
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Invest New Drugs. 2018 Feb;36(1):156-162
pubmed: 28762171
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):611-621
pubmed: 31109808